Efruxifermin for NASH-related cirrhosis
Part of Digestive system clinical trials.
This study tests a new medication called efruxifermin for people with cirrhosis (liver scarring) caused by NASH, a type of fatty liver disease. The goal is to see if the drug can help improve liver health and prevent further damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis (liver scarring) caused by a type of fatty liver disease called NASH.
- For Cohort 1, a liver biopsy must show active NASH, or you have fatty liver along with at least two metabolic conditions (like diabetes, high blood pressure, or obesity).
- For Cohort 2, cirrhosis can be diagnosed by biopsy or a non-invasive test.
- You cannot have other liver diseases (like hepatitis B or C).
- You cannot have type 1 diabetes or unstable type 2 diabetes.
- You cannot have had complications from liver disease (like fluid in the belly or bleeding in the esophagus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This Phase 2 study tests whether SNP-610 (or a placebo) can improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It also checks safety by comparing outcomes between the two groups.
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Hear when a new NASH - Nonalcoholic Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.